Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TVRD
stocks logo

TVRD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast TVRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVRD is 16.00 USD with a low forecast of 4.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast TVRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVRD is 16.00 USD with a low forecast of 4.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 4.180
sliders
Low
4.00
Averages
16.00
High
46.00
Current: 4.180
sliders
Low
4.00
Averages
16.00
High
46.00
Raymond James
Outperform -> Market Perform
downgrade
2025-10-14
Reason
Raymond James
Price Target
2025-10-14
downgrade
Outperform -> Market Perform
Reason
Raymond James downgraded Tvardi Therapeutics to Market Perform from Outperform without a price target. The firm believes many open questions remain regarding TTI-101 following the unsuccessful REVERT-IPF readout. The discontinuation rate seen in the readout adds risk to this program, the analyst tells investors in a research note. Raymond James downgraded Tvardi to reflect the removal of the idiopathic pulmonary fibrosis opportunity and uncertainty on the path forward.
Raymond James
Outperform
initiated
$62
2025-07-14
Reason
Raymond James
Price Target
$62
2025-07-14
initiated
Outperform
Reason
Raymond James initiated coverage of Tvardi Therapeutics with an Outperform rating and $62 price target. The company is developing TTI-101 in idiopathic pulmonary fibrosis, an indication where blockbuster antifibrotics "have left plenty of room for improvement," the analyst tells investors in a research note. The firm believes TTI-101's clinical efficacy and safety profile so far provides strong therapeutic evidence.
Cantor Fitzgerald
NULL -> Overweight
initiated
$52
2025-07-11
Reason
Cantor Fitzgerald
Price Target
$52
2025-07-11
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Tvardi Therapeutics with an Overweight rating and $52 price target.
Piper Sandler
Yasmeen Rahimi
Overweight
initiated
$78
2025-06-12
Reason
Piper Sandler
Yasmeen Rahimi
Price Target
$78
2025-06-12
initiated
Overweight
Reason
Oppenheimer
Outperform
initiated
$65
2025-05-21
Reason
Oppenheimer
Price Target
$65
2025-05-21
initiated
Outperform
Reason
BTIG
initiated
$55
2025-05-15
Reason
BTIG
Price Target
$55
2025-05-15
initiated
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tvardi Therapeutics Inc (TVRD.O) is -1.69, compared to its 5-year average forward P/E of -6.29. For a more detailed relative valuation and DCF analysis to assess Tvardi Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.29
Current PE
-1.69
Overvalued PE
-2.06
Undervalued PE
-10.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TVRD News & Events

Events Timeline

(ET)
2025-11-13
16:03:51
Tvardi Therapeutics Announces Q3 EPS of 59c, Below Consensus Estimate of 96c
select
2025-10-13 (ET)
2025-10-13
07:45:21
Tvardi Reports No Observed Benefit of TTI-101 Treatment in REVERT Trial
select
2025-08-18 (ET)
2025-08-18
08:30:02
Eight Options Set for Delisting on August 18th
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-04PRnewswire
Faruqi & Faruqi Investigates Investor Losses in Tvardi Therapeutics
  • Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Tvardi Therapeutics, Inc. due to significant losses suffered by investors in the company's stock or options, indicating potential legal risks and impacts on investor confidence regarding the company's future.
  • Significant Investor Losses: On October 13, 2025, shares of Moonlake Immunotherapeutics plummeted over 80% following disappointing preliminary data from the Phase 2 REVERT clinical trial, which not only affected investors' financial positions but may also lead to diminished confidence in related biotech investments.
  • Clinical Trial Failure: The TTI-101 Phase 2 trial for idiopathic pulmonary fibrosis failed to meet its goals, with preliminary data showing significant differences in lung function changes between treatment and placebo groups, potentially impacting future R&D investments and market performance.
  • Legal Consultation Opportunity: Faruq & Faruqi encourages affected investors to reach out directly for legal consultation, demonstrating the firm's proactive stance in protecting investor rights.
[object Object]
Preview
7.0
11-30PRnewswire
Faruqi & Faruqi Investigates Investor Losses in Tvardi Therapeutics
  • Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Tvardi Therapeutics, indicating that the company may face legal risks which could affect investor confidence.
  • Investor Losses Highlighted: The firm encourages investors who suffered significant losses in Tvardi stock or options to reach out directly, reflecting a commitment to protecting investor rights and potentially impacting the company's reputation.
  • Law Firm's Credibility: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions for investors, showcasing its expertise in securities law, which may have significant implications for Tvardi's legal outcomes.
  • Market Reaction Anticipated: As the investigation unfolds, Tvardi's stock price may come under pressure, prompting investors to monitor subsequent legal developments and their potential impact on the company's financial health.
[object Object]
Preview
7.0
11-29Globenewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Looks into Claims for Tvardi Therapeutics Investors

  • Investor Support: Faruqi & Faruqi, LLP is encouraging investors who have experienced significant losses in Tvardi stock to contact partner Josh Wilson for legal advice and options.

  • Firm Background: Faruqi & Faruqi is a prominent national securities law firm with a history of recovering substantial amounts for investors since its establishment in 1995.

  • Moonlake Immunotherapeutics Update: Moonlake Immunotherapeutics' shares dropped over 80% following disappointing results from a Phase 2 clinical trial for TTI-101, which did not meet its study goals.

  • Contact Information: Investors can learn more about the Tvardi investigation by visiting the firm's website or calling Josh Wilson directly for assistance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tvardi Therapeutics Inc (TVRD) stock price today?

The current price of TVRD is 4.18 USD — it has increased 1.46 % in the last trading day.

arrow icon

What is Tvardi Therapeutics Inc (TVRD)'s business?

Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

arrow icon

What is the price predicton of TVRD Stock?

Wall Street analysts forecast TVRD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVRD is 16.00 USD with a low forecast of 4.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tvardi Therapeutics Inc (TVRD)'s revenue for the last quarter?

Tvardi Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Tvardi Therapeutics Inc (TVRD)'s earnings per share (EPS) for the last quarter?

Tvardi Therapeutics Inc. EPS for the last quarter amounts to -0.59 USD, decreased -72.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tvardi Therapeutics Inc (TVRD)'s fundamentals?

The market is revising No Change the revenue expectations for Tvardi Therapeutics, Inc. (TVRD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -86.56%.
arrow icon

How many employees does Tvardi Therapeutics Inc (TVRD). have?

Tvardi Therapeutics Inc (TVRD) has 10 emplpoyees as of December 05 2025.

arrow icon

What is Tvardi Therapeutics Inc (TVRD) market cap?

Today TVRD has the market capitalization of 35.18M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free